Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Mizuho from $7.00 to $9.00. They now have an "outperform" rating on the stock.
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference